Obstructive lung disease

ndd’s New Inline Filters Offer Additional Protection Against COVID-19 During Lung Function Tests

Tuesday, July 21, 2020 - 1:43pm

ndd Medical Technologies (ndd), a leading provider of diagnostic technology enabling healthcare professionals the early detection of COPD and other chronic lung diseases, has introduced single patient-use, inline filters for its lung function testing devices in response to COVID-19.

Key Points: 
  • ndd Medical Technologies (ndd), a leading provider of diagnostic technology enabling healthcare professionals the early detection of COPD and other chronic lung diseases, has introduced single patient-use, inline filters for its lung function testing devices in response to COVID-19.
  • Ensuring added safety, the filters complement ndds revolutionary, highly portable EasyOne spirometry range, including EasyOne Air, Pro, and Pro LAB.
  • ndds popular spirometers are of the most sensitive devices available, delivering reliable, real-time lung function results and enabling specialists diagnoses of chronic lung diseases, even at point of care.
  • COVID-19 has massively impacted healthcare systems and there is growing research into lung function post-infection.

Renovion Announces Completion of $8.1 Million Financing Round Enabling Clinical Programs in Chronic Inflammatory Lung Diseases

Thursday, June 18, 2020 - 1:00pm

Renovion, Inc., a biopharmaceutical company on a mission to transform the treatment of chronic inflammatory lung diseases, announced completion of a Series A financing round of $8.1 million to fund the development and clinical programs associated with their lead therapeutic candidate ARINA-1.

Key Points: 
  • Renovion, Inc., a biopharmaceutical company on a mission to transform the treatment of chronic inflammatory lung diseases, announced completion of a Series A financing round of $8.1 million to fund the development and clinical programs associated with their lead therapeutic candidate ARINA-1.
  • ARINA-1 is a nebulized therapy developed to improve mucus clearance and decrease inflammation in patients diagnosed with chronic lung disease.
  • This funding will be instrumental in progressing our clinical programs in patients suffering from chronic lung diseases, including patients with a lung transplant, cystic fibrosis (CF), and non-CF bronchiectasis.
  • The company is focused on developing ARINA-1 for orphan chronic inflammatory lung diseases.

Nuvaira Announces FDA Breakthrough Designation for AIRFLOW-3 Pivotal Trial Device

Monday, June 8, 2020 - 2:05pm

MINNEAPOLIS, June 8, 2020 /PRNewswire/ -- Nuvaira , a developer of novel therapeutic strategies to treat obstructive lung diseases, has announced that its Nuvaira Lung Denervation System has been designated as a Breakthrough Device by the U.S. Food and Drug Administration (FDA).

Key Points: 
  • MINNEAPOLIS, June 8, 2020 /PRNewswire/ -- Nuvaira , a developer of novel therapeutic strategies to treat obstructive lung diseases, has announced that its Nuvaira Lung Denervation System has been designated as a Breakthrough Device by the U.S. Food and Drug Administration (FDA).
  • Nuvaira's lung denervation system is designed to reduce the risk of moderate-to-severe COPD exacerbations in patients on optimal medical care.
  • Nuvaira also announces appointment of Tim Herbert, President & CEO of Minneapolis-based Inspire Medical Systems to its Board of Directors.
  • Nuvaira and dNerva are registered trademarks of Nuvaira, Inc.
    View original content to download multimedia: http://www.prnewswire.com/news-releases/nuvaira-announces-fda-breakthrou...

Deborah Heart and Lung Center Introduces Remote Patient Monitoring for COPD Patients

Tuesday, May 26, 2020 - 12:00pm

BROWNS MILLS, N.J., May 26, 2020 /PRNewswire-PRWeb/ --Deborah Heart and Lung Center, New Jersey's only specialty heart, lung, and vascular hospital, and an Alliance member of the Cleveland Clinic Heart, Vascular & Thoracic Institute, has announced the introduction of remote patient monitoring for patients diagnosed with chronic obstructive pulmonary disease (COPD).

Key Points: 
  • BROWNS MILLS, N.J., May 26, 2020 /PRNewswire-PRWeb/ --Deborah Heart and Lung Center, New Jersey's only specialty heart, lung, and vascular hospital, and an Alliance member of the Cleveland Clinic Heart, Vascular & Thoracic Institute, has announced the introduction of remote patient monitoring for patients diagnosed with chronic obstructive pulmonary disease (COPD).
  • Patients diagnosed with COPD require physician monitoring to prevent the disease from progressing.
  • With the expansion of telemedicine and remote monitoring services prompted by the Coronavirus epidemic, Deborah has instituted a new remote patient monitoring services platform.
  • Called HGE Care the remote monitoring platform is designed for COPD patients who have been discharged from the hospital and are recuperating at home.

4DMedical's Lung Imaging Technology Receives FDA Clearance as COVID-19 Intensifies Global Focus on Respiratory Health

Monday, May 25, 2020 - 11:00am

The clearance comes at a time when there has never been a greater focus on respiratory health around the world, as countries deal with the COVID-19 pandemic.

Key Points: 
  • The clearance comes at a time when there has never been a greater focus on respiratory health around the world, as countries deal with the COVID-19 pandemic.
  • "FDA clearance means we can fast track our 'go-to-market' strategy to ensure hospitals and doctors in the United States have almost immediate access to our XV Technology Ventilation Reports," added Fouras.
  • 4DMedical's XV Technology is supported by 15 years of preclinical and clinical trials and ongoing collaborations with leading hospitals worldwide.
  • 4DMedical is a medical technology company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders including: coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer.

Surge in Demand for Anti-asthmatics and COPD Drugs due to Coronavirus, Reports TBRC

Tuesday, April 28, 2020 - 4:30pm

This has created a sudden rise in demand for anti-asthmatics and COPD drugs.

Key Points: 
  • This has created a sudden rise in demand for anti-asthmatics and COPD drugs.
  • Request A Free Sample Of The Anti-Asthmatic And COPD Drugs Market Report: https://www.thebusinessresearchcompany.com/sample.aspx?id=2417&type=smp
    The anti-asthmatics and COPD drugs market consists of sales of anti-asthmatics and COPD drugs by entities (organizations, sole traders and partnerships) that manufacture anti-asthmatics and COPD drugs which are used to prevent and treat asthma and chronic obstructive pulmonary disease (COPD).
  • The anti-asthmatics and COPD drug industry includes establishments that manufacture anti-asthmatics and COPD drugs such as bronchodilators, anti-inflammatory drugs, monoclonal antibodies and combination drugs.
  • The anti-asthmatics and COPD drugs market is segmented by class into bronchodilators, anti-inflammatory drugs, monoclonal antibodies, and combination drugs.

Global Chronic Obstructive Pulmonary Disease Industry (2018 to 2028) - Drug Forecast and Market Analysis - ResearchAndMarkets.com

Tuesday, April 28, 2020 - 12:37pm

The "Chronic Obstructive Pulmonary Disease: Global Drug Forecast and Market Analysis to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chronic Obstructive Pulmonary Disease: Global Drug Forecast and Market Analysis to 2028" report has been added to ResearchAndMarkets.com's offering.
  • Chronic obstructive pulmonary disease (COPD) is a common, preventable, incurable, and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation.
  • Long-term exposure to noxious particles or gases such as cigarette smoke and environmental pollution can induce chronic inflammation in the airways, subsequently causing alveolar abnormalities.
  • This leads to airflow limitation and causes structural abnormalities such as obstructive bronchiolitis and parenchymal destruction (emphysema).

Take Action to Breathe Better

Monday, April 13, 2020 - 7:20pm

MISSION, Kan., April 13, 2020 /PRNewswire/ --(Family Features) More than 25 million Americans (about 1 in 13 people) suffer from asthma, according to the Centers for Disease Control and Prevention's National Health Interview Survey.

Key Points: 
  • MISSION, Kan., April 13, 2020 /PRNewswire/ --(Family Features) More than 25 million Americans (about 1 in 13 people) suffer from asthma, according to the Centers for Disease Control and Prevention's National Health Interview Survey.
  • Asthma is a serious lung disease that affects the airways and makes it difficult to breathe.
  • However, symptoms can be controlled with proper treatment and an action plan similar to this recommendation from the National Heart, Lung, and Blood Institute.
  • Find more information at nhlbi.nih.gov/LMBBasthma .

Ozone Exposure Associated with Asthma Symptoms

Tuesday, February 4, 2020 - 12:00pm

This prompted CommonSpirit to study environmental factors that could be worsening asthma symptoms for its patients.

Key Points: 
  • This prompted CommonSpirit to study environmental factors that could be worsening asthma symptoms for its patients.
  • Researchers gave connected inhalers to 287 patients in the two areas to manage and track the onset of asthma symptoms.
  • They were able to capture the date, time and location of medication use and determine whether that use was associated with increased levels of ozone in the air.
  • When ozone reaches unhealthy levels, it can cause wheezing, shortness of breath and other adverse symptoms, particularly in people with pre-existing respiratory illnesses such as asthma or chronic obstructive pulmonary disease (COPD).

Chronic Obstructive Pulmonary Disease: Epidemiology Forecast to 2028 - ResearchAndMarkets.com

Monday, February 3, 2020 - 4:50pm

The "Chronic Obstructive Pulmonary Disease: Epidemiology Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chronic Obstructive Pulmonary Disease: Epidemiology Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
  • Chronic Obstructive Pulmonary Disease (COPD) is a progressive disease characterized by coughing that produces large amounts of mucus, difficulty in breathing, shortness of breath (initially with exertion), wheezing, chest tightness, and other respiratory symptoms.
  • The most commonly used severity criteria is the Global Initiative for Chronic Obstructive Lung Disease (GOLD) standard.
  • The Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Report provides an overview of the risk factors and global trends of COPD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).